Lung Cancer Dispatch
4.5K views | +0 today
Follow
Lung Cancer Dispatch
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Scooped by Cancer Commons
Scoop.it!

Abraxane-Paraplatin Combination May be Safe and Effective in Elderly Patients with Advanced Lung Cancer

A recent study examined first-line treatment with the chemotherapy agent carboplatin (Paraplatin) combined with either albumin-bound paclitaxel (Abraxane) or standard solvent-based paclitaxel (Taxol) in both elderly and younger patients with advanced non-small cell lung cancer (NSCLC). Patients treated with Abraxane/Paraplatin exhibited higher treatment response rates and fewer toxic side effects in both age groups, and elderly patients (age 70+ years) experienced longer periods without cancer progression and longer overall survival with Abraxane/Paraplatin compared to Taxol/Paraplatin treatment. Abraxane plus Paraplatin may constitute a safe, effective first-line treatment for elderly patients with advanced NSCLC, a group that has been traditionally undertreated.


Research paper: http://annonc.oxfordjournals.org/content/24/2/314.long

Cancer Commons's insight:

Annals of Oncology | Nov 2, 2012

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

FDA Approves Abraxane for Treatment of Advanced NSCLC

FDA Approves Abraxane for Treatment of Advanced NSCLC | Lung Cancer Dispatch | Scoop.it

The FDA has approved the use of breast cancer drug Abraxane in conjunction with carboplatin for non-small cell lung cancer (NSCLC) treatment. Abraxane, manufactured by Celgene Corp., combines paclitaxel with a protein called albumin. Earlier this year, a large clinical trial found Abraxane plus carboplatin to be more effective in shrinking advanced NSCLC tumors than the standard paclitaxel drug Taxol plus carboplatin. Abraxane treatment may be particularly effective for patients with squamous NSCLC patients age 70 years or older and North American patients.

Cancer Commons's insight:

Huffington Post | Oct 12, 2012

more...
No comment yet.